


Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics

Review Published: 26 August 2025

Volume 59, pages 315–328, (2025) Cite this article



Nuclear Medicine and Molecular Imaging

Aims and scope

Submit manuscript



Zahra Shaghghi, Sahar Nosrati, Ramin Mansouri & Maryam Alvandi 

 61 Accesses  1 Citation [Explore all metrics](#) →

Abstract

Radiolabeled magnetic nanoparticles (MNPs), particularly superparamagnetic iron oxide nanoparticles (SPIONs), have gained significant attention in the field of cancer theranostics due to their potential in targeted therapy and molecular imaging. This review highlights recent advancements in the development of various radiolabeled SPIONs, including those functionalized with polyethylene glycol (PEG), DTPA, and other targeting agents. These nanoparticles are designed for multiple clinical applications, including hyperthermia, magnetic resonance imaging (MRI), and radiotherapy. However, the translation of these promising nanostructures into clinical practice faces several challenges, such as issues with surface functionalization, toxicity, stability, and the

complexities of multimodal imaging. The review also explores creative approaches to overcome these challenges, such as designing multicomponent nanostructures, utilizing chelator-based and chelator-free radiolabeling techniques, employing click chemistry for radiolabeling, and enhancing biocompatibility methods. Ultimately, radiolabeled SPIONs have the potential to revolutionize cancer treatment and imaging, but further optimization is required to overcome existing obstacles and enhance their clinical applicability.

 This is a preview of subscription content, [log in via an institution](#)  to check access.

Access this article

[Log in via an institution](#)

Subscribe and save

 Springer+

from €37.37 /Month

Starting from 10 chapters or articles per month

Access and download chapters and articles from more than 300k books and 2,500 journals

Cancel anytime

[View plans](#) 

Buy Now

[Buy article PDF 39,95 €](#)

Price includes VAT (Iran)

Instant access to the full article PDF.


[Institutional subscriptions](#) →

Similar content being viewed by others




Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as Multifunctional...

Chapter | © 2020



Exploring the Role of Magnetic Nanoparticles in Cancer Imaging and Diagnostic...

Chapter | © 2025



A Novel Strategy for the Surface Modification of Superparamagnetic (Fe₃O₄) Iron Oxide...

Chapter | © 2019

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

[Cancer Nanotechnology](#)

[Molecular Imaging](#)

[Molecularly targeted therapy](#)

[Nanomaterial](#)

[Nanomedicine and Nanotoxicology](#)

[Nanoparticles](#)

Data Availability

Data sharing not applicable to this article as no datasets were generated in the current study.

References

1. Farzanegan Z, Tahmasbi M. Magnetic nanoparticles based hyperthermia for cancer treatment: A systematic review. 2022.

[PubMed](#) [Google Scholar](#)
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.

[PubMed](#) [Google Scholar](#)
3. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M. Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer; 2018.

[Google Scholar](#)
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49.

[PubMed](#) [Google Scholar](#)
5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Cancer J Clin*. 2024;74(3):229–63.

[Article](#) [Google Scholar](#)
6. Torre L, Siegel R, Jemal A. Global cancer facts & figures. Atlanta: American Cancer Society. 2015;2.
7. Talluri S, Malla RR. Superparamagnetic iron oxide nanoparticles (SPIONs) for diagnosis and treatment of breast, ovarian and cervical cancers. *Curr Drug Metab*. 2019;20(12):942–5.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

8. Lamichhane N, Sharifabad ME, Hodgson B, Mercer T, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs) as therapeutic and diagnostic agents. *Nanoparticle therapeutics*: Elsevier; 2022. pp. 455–97.

[Google Scholar](#)

9. Hadei SK, Alvandi M, Ramezani M, Aloosh O, Shaghghi Z, Moradi A. Applying wells score to inconclusive perfusion only modified PIOPED II (prospective investigation of pulmonary embolism diagnosis II) readings in order to optimize the lung scintigraphy diagnostic yield in acute pulmonary embolism detection. *Ann Nucl Med*. 2020;34:521–6.

[Article](#) [PubMed](#) [Google Scholar](#)

10. Awad NS, Salkho NM, Abuwatfa WH, Paul V, AlSawaftah NM, Hussein GA. Tumor vasculature vs tumor cell targeting: understanding the latest trends in using functional nanoparticles for cancer treatment. *OpenNano*. 2023;11:100136.

[Article](#) [CAS](#) [Google Scholar](#)

11. McKay A, Pantoja C, Hall R, Matthews S, Spalding P, Banerjee R. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. *J Patient-Reported Outcomes*. 2021;5:1–14.

[Article](#) [Google Scholar](#)

12. Yu Y, Jain B, Anand G, Heidarian M, Lowe A, Kalra A. Technologies for non-invasive physiological sensing: status, challenges, and future horizons. *Biosens Bioelectronics: X*. 2024;16:100420.

[CAS](#) [Google Scholar](#)

13. Feng Z, Fan H, Cheng L, Zhang H, Fan H, Liu J. Advanced biomimetic nanomaterials for non-invasive disease diagnosis. *Front Mater.* 2021;8: 664795.

[Article](#) [Google Scholar](#)

14. Hussain S, Mubeen I, Ullah N, Shah S, Khan BA, Zahoor M, et al. Modern diagnostic imaging technique applications and risk factors in the medical field: A review. *Biomed Res Int.* 2022;2022:5164970.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

15. Vangijzegem T, Lecomte V, Ternad I, Van Leuven L, Muller RN, Stanicki D, Laurent S. Superparamagnetic iron oxide nanoparticles (SPION): from fundamentals to state-of-the-art innovative applications for cancer therapy. *Pharmaceutics.* 2023;15(1):236.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

16. Singh V, Theranostics. Integrated diagnostics and therapy using nanomedicine. *Nanomedicine: Springer;* 2024. pp. 505–30.

[Google Scholar](#)

17. Jeyamogan S, Khan NA, Siddiqui R. Application and importance of theranostics in the diagnosis and treatment of cancer. *Arch Med Res.* 2021;52(2):131–42.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

18. Kang SJ, Jeong HY, Kim MW, Jeong IH, Choi MJ, You YM, et al. Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis. *Nanoscale.* 2018;10(41):19338–50.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

19. Alromi D, Seifalian A. Emerging application of magnetic nanoparticles for diagnosis and treatment of cancer. *Polymers*. 2021;13.

20. Hazarika D, Sarma S, Shankarishan P. Nanotechnology in cancer therapeutics, diagnosis, and management. *BioTechnologia*. 2024;105(3):287–303.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

21. Nwabunwanne C, Aisida SO, Javed R, Akpomie kG, Awada C, Alshoaibi A, Ezema F. Magnetic nanoparticles: biosynthesis, characterization, surface functionalization and biomedical applications. *J Indian Chem Soc*. 2025;102(3):101617.

[Article](#) [CAS](#) [Google Scholar](#)

22. Colombo M, Carregal-Romero S, Casula MF, Gutiérrez L, Morales MP, Böhm IB, et al. Biological applications of magnetic nanoparticles. *Chem Soc Rev*. 2012;41(11):4306–34.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

23. Kafrouni L, Savadogo O. Recent progress on magnetic nanoparticles for magnetic hyperthermia. *Prog Biomater*. 2016;5(3):147–60.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

24. Albarqi HA, Wong LH, Schumann C, Sabei FY, Korzun T, Li X, et al. Biocompatible nanoclusters with high heating efficiency for systemically delivered magnetic hyperthermia. *ACS Nano*. 2019;13(6):6383–95.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

25. Włodarczyk A, Gorgoń S, Radoń A, Bajdak-Rusinek K. Magnetite nanoparticles in magnetic hyperthermia and cancer therapies: challenges and perspectives. *Nanomaterials*. 2022;12(11):1807.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

26. Falagan-Lotsch P, Grzincic EM, Murphy CJ. New advances in nanotechnology-based diagnosis and therapeutics for breast cancer: an assessment of active-targeting inorganic nanoplatforms. *Bioconjug Chem.* 2017;28(1):135–52.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

27. Shabestari Khiabani S, Farshbaf M, Akbarzadeh A, Davaran S. Magnetic nanoparticles: preparation methods, applications in cancer diagnosis and cancer therapy. *Artif Cells Nanomed Biotechnol.* 2017;45(1):6–17.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

28. Song J, Hu Q, Huang J, Chen T, Ma Z, Shi H. MR targeted imaging for the expression of tenascin-C in cervical cancer. *Br J Radiol.* 2018;91(1090): 20170681.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

29. Yin X, Russek SE, Zabow G, Sun F, Mohapatra J, Keenan KE, et al. Large T1 contrast enhancement using superparamagnetic nanoparticles in ultra-low field MRI. *Sci Rep.* 2018;8(1):11863.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

30. Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. *Science.* 2022;375(6586):eaay9040.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

31. Frantellizzi V, Conte M, Pontico M, Pani A, Pani R, De Vincentis G. New frontiers in molecular imaging with superparamagnetic iron oxide nanoparticles (SPIONs): efficacy, toxicity, and future applications. *Nucl Med Mol Imaging.* 2020;54:65–80.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

32. Lassenberger A, Scheberl A, Stadlbauer A, Stiglbauer A, Helbich T, Reimhult E. Individually stabilized, superparamagnetic nanoparticles with controlled shell and size leading to exceptional stealth properties and high relaxivities. *ACS Appl Mater Interfaces*. 2017;9(4):3343–53.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

33. Uthaman S, Lee SJ, Cherukula K, Cho C-S, Park I-K. Polysaccharide-coated magnetic nanoparticles for imaging and gene therapy. *Biomed Res Int*. 2015;2015(1):959175.

[PubMed](#) [PubMed Central](#) [Google Scholar](#)

34. Akhtar N, Mohammed HA, Yusuf M, Al-Subaiyel A, Sulaiman GM, Khan RA. SPIONs conjugate supported anticancer drug doxorubicin's delivery: current status, challenges, and prospects. *Nanomaterials*. 2022;12(20):3686.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

35. Suciu M, Ionescu C, Ciorîță A, Tripon S, Nica D, Al-Salami H, Barbu-Tudoran L. Applications of superparamagnetic iron oxide nanoparticles in drug and therapeutic delivery, and biotechnological advancements. *Beilstein J Nanotechnol*. 2020;11:1092–109.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

36. Lapusan R, Borlan R, Focsan M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. *Nanoscale Adv*. 2024;6(9):2234–59. <https://doi.org/10.1039/D3NA01064C>

37. Xing Y, Zhao J, Conti PS, Chen K. Radiolabeled nanoparticles for multimodality tumor imaging. *Theranostics*. 2014;4(3):290–306.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

38. Bentivoglio V, Varani M, Lauri C, Ranieri D, Signore A. Methods for radiolabelling nanoparticles: PET use (Part 2). *Biomolecules*. 2022;12(10):1517.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

39. Pellico J, Gawne PJ, de Rosales RT. Radiolabelling of nanomaterials for medical imaging and therapy. *Chem Soc Rev*. 2021;50(5):3355–423.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

40. de Souza Albernaz M, Toma SH, Clanton J, Araki K, Santos-Oliveira R. Decorated superparamagnetic iron oxide nanoparticles with monoclonal antibody and diethylene-triamine-pentaacetic acid labeled with technetium-99m and gallium-68 for breast cancer imaging. *Pharm Res*. 2018;35:1–9.

[Article](#) [Google Scholar](#)

41. Enrique M-A, Mariana O-R, Mirshojaei SF, Ahmadi A. Multifunctional radiolabeled nanoparticles: strategies and novel classification of radiopharmaceuticals for cancer treatment. *J Drug Target*. 2015;23(3):191–201.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

42. Farzin L, Sheibani S, Moassesi ME, Shamsipur M. An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions. *J Biomed Mater Res A*. 2019;107(1):251–85.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

43. Nosrati S, Shanehsazzadeh S, Yousefnia H, Gholami A, Grüttner C, Jalilian AR, et al. Biodistribution evaluation of ^{166}Ho -DTPA-SPION in normal rats. *J Radioanal Nucl Chem.* 2016;307:1559–66.

[Article](#) [CAS](#) [Google Scholar](#)

44. Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. *Molecules.* 2022;27(16):5231.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

45. Forte E, Fiorenza D, Torino E, Costagliola di Polidoro A, Cavaliere C, Netti PA, et al. Radiolabeled PET/MRI nanoparticles for tumor imaging. *J Clin Med.* 2019;9(1):89.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

46. Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G. Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. *Int J Radiat Biol.* 2019;95(5):554–61.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

47. Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, et al. Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castration resistant prostate cancer: A critical review. *Medicine.* 2019;98(19):e15608.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

48. Karakatsanis A, Daskalakis K, Stålberg P, Olofsson H, Andersson Y, Eriksson S, et al. Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. *Br J Surg.* 2017;104(12):1675–85.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

49. Mehralivand S, van der Poel H, Winter A, Choyke PL, Pinto PA, Turkbey B. Sentinel lymph node imaging in urologic oncology. *Transl Androl Urol*. 2018;7(5):887–902.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

50. Staník M, Macík D, Čapák I, Marečková N, Lžíčářová E, Doležel J. Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: early clinical experience. *Int Urol Nephrol*. 2018;50(8):1427–33.

[Article](#) [PubMed](#) [Google Scholar](#)

51. Winter A, Tobias K, Susanne PT, Philipp G, Svenja E, Holger G, et al. Magnetic resonance Sentinel lymph node imaging and magnetometer-guided intraoperative detection in prostate cancer using superparamagnetic iron oxide nanoparticles. *Int J Nanomed*. 2018;13(null):6689–98.

[Article](#) [CAS](#) [Google Scholar](#)

52. Mekseriwattana W, Srisuk S, Kriangsaksri R, Niamsiri N, Prapainop K. The impact of serum proteins and surface chemistry on magnetic nanoparticle colloidal stability and cellular uptake in breast cancer cells. *AAPS PharmSciTech*. 2019;20:1–9.

[Article](#) [Google Scholar](#)

53. Zhang L, Jin R, Sun R, Du L, Liu L, Zhang K, et al. Superparamagnetic iron oxide nanoparticles as magnetic resonance imaging contrast agents and induced autophagy response in endothelial progenitor cells. *J Biomed Nanotechnol*. 2019;15(2):396–404.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

54. Patil RM, Thorat ND, Shete PB, Bedge PA, Gavde S, Joshi MG, et al. Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles. *Biochem Biophys Rep*. 2018;13:63–72.

[PubMed](#) [PubMed Central](#) [Google Scholar](#)

55. Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). *Nano Reviews*. 2010;1(1):53–8.

[Article](#) [Google Scholar](#)

56. Radović M, Calatayud MP, Goya GF, Ibarra MR, Antić B, Spasojević V, et al. Preparation and in vivo evaluation of multifunctional ^{90}Y -labeled magnetic nanoparticles designed for cancer therapy. *J Biomedical Mater Res Part A*. 2015;103(1):126–34.

[Article](#) [Google Scholar](#)

57. Mokhodoeva O, Vlk M, Nykl E, Kukleva E, Suchánková P, Stamberg K et al. Study of ^{223}Ra uptake mechanism by Fe_3O_4 nanoparticles: towards new prospective theranostic spions. *J Nanopart Res*. 2016;18.

58. Gawęda W, Pruszyński M, Cędrowska E, Rodak M, Majkowska-Pilip A, Gawęł D, et al. Trastuzumab modified barium ferrite magnetic nanoparticles labeled with radium-223: a new potential radiobioconjugate for alpha radioimmunotherapy. *Nanomaterials*. 2020;10(10):2067.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

59. Cędrowska E, Pruszyński M, Gawęda W, Żuk M, Krysiński P, Bruchertseifer F, et al. Trastuzumab conjugated superparamagnetic iron oxide nanoparticles labeled with ^{225}Ac as a perspective tool for combined α -radioimmunotherapy and magnetic hyperthermia of HER2-positive breast cancer. *Molecules*. 2020;25(5):1025.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

60. Anitha K, Chenchula S, Surendran V, Shvetank B, Ravula P, Milan R, et al. Advancing cancer theranostics through biomimetics: a comprehensive review. *Heliyon*. 2024.

<https://doi.org/10.1016/j.heliyon.2024.e27692>.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

61. Zarepour A, Zarrabi A, Khosravi A, Zarepour A, Zarrabi A, Khosravi A. Spions as nano-theranostics agents: Springer; 2017.
62. Anijdan SM, Gholami A, Lahooti A. Development of radiolabeled dextran coated iron oxide nanoparticles with ^{111}In and its biodistribution studies. *Int J Radiation Res.* 2020;18(3):539–47.

[Google Scholar](#)

63. Gholami A, Anijdan SHM. Development of ^{153}Sm -DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI. *Iran J Basic Med Sci.* 2016;19(10):1056.

[PubMed](#) [PubMed Central](#) [Google Scholar](#)

64. Shanehsazzadeh S, Grüttner C, Yousefnia H, Lahooti A, Gholami A, Nosrati S, et al. Development of ^{177}Lu -DTPA-SPIO conjugates for potential use as a dual contrast SPECT/MRI imaging agent. *Radiochim Acta.* 2016;104(5):337–44.

[Article](#) [CAS](#) [Google Scholar](#)

65. Stephen ZR. *Magnetic Nanoparticles for Targeted Cancer Theranostics.* 2016.

66. Wang L, Shi Y, Jiang J, Li C, Zhang H, Zhang X, et al. Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. *Small.* 2022;18(45): 2203678.

[Article](#) [CAS](#) [Google Scholar](#)

67. Carter TJ, Agliardi G, Lin FY, Ellis M, Jones C, Robson M, et al. Potential of magnetic hyperthermia to stimulate localized immune activation. *Small*. 2021;17(14):2005241.

[Article](#) [CAS](#) [Google Scholar](#)

68. Gordon MR, Zhuang J, Ventura J, Li L, Raghupathi K, Thayumanavan S. Biodistribution analysis of NIR-labeled nanogels using in vivo FMT imaging in triple negative human mammary carcinoma models. *Mol Pharm*. 2018;15(3):1180–91.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

69. Gawęda W, Osial M, Żuk M, Pękała M, Bilewicz A, Kryszynski P. Lanthanide-doped spions bioconjugation with trastuzumab for potential multimodal anticancer activity and magnetic hyperthermia. *Nanomaterials*. 2020;10(2):288.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

70. Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. *Polymers*. 2022;14(13):2601.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

71. Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. *J Personalized Med*. 2021;11(8):771.

[Article](#) [Google Scholar](#)

72. Chen C, Jianxian G, Gao Y, Chen L, Cui J, Zeng J, Gao M. Ultrasmall superparamagnetic iron oxide nanoparticles: A next generation contrast agent for magnetic resonance imaging. *WIREs Nanomed Nanobiotechnol*. 2021;14.

73. Papadopoulou S, Kolokithas-Ntoukas A, Salvanou E-A, Gaitanis A, Xanthopoulos S, Avgoustakis K, et al. Chelator-free/chelator-mediated radiolabeling of colloiddally stabilized iron oxide nanoparticles for biomedical imaging. *Nanomaterials*. 2021;11(7):1677.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

74. Azadbakht B, Afarideh H, Ghannadi-Maragheh M, Bahrami-Samani A, Asgari M. Preparation and evaluation of APTES-PEG coated iron oxide nanoparticles conjugated to rhenium-188 labeled rituximab. *Nucl Med Biol*. 2017;48:26–30.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

75. Aboushoushah SF. Iron oxide nanoparticles enhancing magnetic resonance imaging: A review of the latest advancements. *J Science: Adv Mater Devices*. 2025;10(2):100875.

76. Shurin MR, Kirichenko VA, Shurin GV, Lee D, Crane C, Kirichenko AV. Radiomodulating properties of superparamagnetic iron oxide nanoparticle (SPION) agent Ferumoxytol on human monocytes: implications for MRI-Guided liver radiotherapy. *Cancers*. 2024;16(7):1318.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

77. Hoffman D, Sun M, Yang L, McDonagh PR, Corwin F, Sundaresan G, et al. Intrinsically radiolabelled [(59)Fe]-SPIONs for dual mri/radionuclide detection. *Am J Nucl Med Mol Imaging*. 2014;4(6):548–60.

[PubMed](#) [PubMed Central](#) [Google Scholar](#)

78. Gholami YH, Yuan H, Wilks MQ, Maschmeyer R, Normandin MD, Josephson L, et al. A radio-nano-platform for T1/T2 dual-mode PET-MR imaging. *Int J Nanomedicine*. 2020;15:1253–66. <https://doi.org/10.2147/IJN.S241971>

79. Zhao R, Lan D, Xia B, Dong M, Mu J, Zhao Y. PET-Based Dual-Modal probes for. In Vivo Imaging Small. 2025;21(8):e2409713.

80. Beer A. PET imaging of integrin $\alpha V\beta 3$ expression. Theranostics. 2011;1:48.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

81. AtiLa DİNÇEr C, GetİRen B, GÖKalp C, Çİplak Z, KarakeÇİLİ A, Yildiz N. An anticancer drug loading and release study to ternary GO-Fe₃O₄-PPy and Fe₃O₄@PPy-NGQDs nanocomposites for photothermal chemotherapy. Colloids Surf A. 2022;633:127791.

[Article](#) [Google Scholar](#)

82. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, et al. cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32(17):4151–60.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

83. Fu J, Chen L, Hu J, Yu C, Yin J. Radiolabelled nanomaterials for diagnostic and therapeutic applications in hepatocellular carcinoma and other liver diseases. Precision Med Eng. 2025;2(1):100018.

[Article](#) [Google Scholar](#)

84. Zhong X, Yan J, Ding X, Su C, Xu Y, Yang M. Recent advances in bioorthogonal click chemistry for enhanced PET and SPECT radiochemistry. Bioconjug Chem. 2023;34(3):457–76.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

85. Ghosal K, Bhattacharyya SK, Mishra V, Zuilhof H. Click chemistry for biofunctional polymers: from observing to steering cell behavior. *Chem Rev.* 2024;124(23):13216–300.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

86. Asad S, Ahl D, Suárez-López YdC, Erdélyi M, Phillipson M, Teleki A. Click Chemistry-Based bioconjugation of iron oxide nanoparticles. *Small.* 2025;21(11):2407883.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

87. Cano M, Núñez-Lozano R, Dumont Y, Larpent C, Cueva-Méndez G. Synthesis and characterization of multifunctional superparamagnetic iron oxide nanoparticles (SPION)/C60 nanocomposites assembled by fullerene-amine click chemistry. *RSC Adv.* 2016;6:70374–82.

88. Natarajan A, Gruettner C, Ivkov R, DeNardo GL, Mirick G, Yuan A, et al. Nanoferrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. *Bioconjug Chem.* 2008;19(6):1211–8.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

89. Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. *J Nanobiotechnol.* 2024;22(1):728.

[Article](#) [CAS](#) [Google Scholar](#)

90. Miao Y, Yang T, Yang S, Yang M, Mao C. Protein nanoparticles directed cancer imaging and therapy. *Nano Convergence.* 2022;9(1):2.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

91. Qu J, Tian Z, Wang Q, Peng S, Luo J-b, Zhou Q-h, Lin J. Surface design and Preparation of multi-functional magnetic nanoparticles for cancer cell targeting, therapy, and imaging. *RSC Adv.* 2018;8(62):35437–47.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

92. Solar P, González G, Vilos C, Herrera N, Juica N, Moreno M, et al. Multifunctional polymeric nanoparticles doubly loaded with SPION and ceftiofur retain their physical and biological properties. *J Nanobiotechnol.* 2015;13:1–12.

[Article](#) [Google Scholar](#)

93. Lyer S, Knopp T, Werner F, Zaloga J, Friedrich R, Trahms L et al. Multifunctional spions for theranostics in cancer. *Int J Magn Part Imaging IJMPI.* 2018;4(1):5.

94. Zhi D, Yang T, Yang J, Fu S, Zhang S. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy. *Acta Biomater.* 2020;102:13–34.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

95. Alvandi M, Shaghaghi Z, Aryafar V, Fariba F, Sanaei Z. The evaluation of left ventricular dyssynchrony in hypertensive patients with a preserved systolic function undergoing gated SPECT myocardial perfusion imaging. *Ann Nucl Med.* 2019;33:899–906.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

96. Naghshtabrizi B, Alvandi M, Shaghaghi Z, Hadei SK, Fariba F, Moradi M, Rabie MAS. Transient ischemic dilation or transient RV visualization in patients with normal SPECT stress myocardial perfusion imaging: correlation with CT coronary artery calcium scoring and coronary angiography. *J Nucl Cardiol.* 2022;29(5):2149–56.

[Article](#) [PubMed](#) [Google Scholar](#)

97. Zolata H, Davani FA, Afarideh H. Synthesis, characterization and theranostic evaluation of indium-111 labeled multifunctional superparamagnetic iron oxide nanoparticles. *Nucl Med Biol.* 2015;42(2):164–70.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

98. Lamb J, Holland JP. Advanced methods for radiolabeling multimodality nanomedicines for SPECT/MRI and PET/MRI. *J Nucl Med.* 2018;59(3):382–9.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

99. Xu M, Qi Y, Liu G, Song Y, Jiang X, Du B. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. *ACS Nano.* 2023;17(21):20825–49.

[Article](#) [PubMed](#) [Google Scholar](#)

100. Lima-Tenorio MK, Pineda EAG, Ahmad NM, Fessi H, Elaissari A. Magnetic nanoparticles: in vivo cancer diagnosis and therapy. *Int J Pharm.* 2015;493(1–2):313–27.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

101. Tsiapa I, Efthimiadou EK, Fragogeorgi E, Loudos G, Varvarigou AD, Bouziotis P, et al. ^{99m}Tc-labeled aminosilane-coated iron oxide nanoparticles for molecular imaging of $\alpha\beta 3$ -mediated tumor expression and feasibility for hyperthermia treatment. *J Colloid Interface Sci.* 2014;433:163–75.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

102. Liang S, Wang Y, Yu J, Zhang C, Xia J, Yin D. Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. *J Mater Sci Mater Med.* 2007;18:2297–302.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

- 103.** Chen J, Wu H, Han D, Xie C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. *Cancer Lett.* 2006;231(2):169–75.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

- 104.** Ferro-Flores G, Ocampo-García E, Santos-Cuevas BL, Morales-Avila C, Azorín-Vega E. Multifunctional radiolabeled nanoparticles for targeted therapy. *Curr Med Chem.* 2014;21(1):124–38.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

- 105.** Natarajan A, Xiong C-Y, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. *Cancer Biother Radiopharm.* 2008;23(1):82–91.

[CAS](#) [PubMed](#) [Google Scholar](#)

- 106.** Chen D, Dougherty CA, Yang D, Wu H, Hong H. Radioactive nanomaterials for multimodality imaging. *Tomography.* 2016;2(1):3–16.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

- 107.** Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. *Science.* 2012;338(6109):903–10.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

- 108.** Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. *Nano Today.* 2009;4(5):399–413.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

109. Hwang DW, Youn H, Lee DS. Molecular imaging using PET/MRI particle. *Open Nucl Med J.* 2010;2(1):186–91.

110. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. *Acc Chem Res.* 2011;44(10):1050–60.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

111. Padmanabhan P, Kumar A, Kumar S, Chaudhary RK, Gulyás B. Nanoparticles in practice for molecular-imaging applications: an overview. *Acta Biomater.* 2016;41:1–16.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

112. Ansari SR, Suárez-López YdC, Thersleff T, Häggström L, Ericsson T, Katsaros I, et al. Pharmaceutical quality by design approach to develop high-performance nanoparticles for magnetic hyperthermia. *ACS Nano.* 2024;18(23):15284–302.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

113. Kandasamy G, Soni S, Sushmita K, Veerapu NS, Bose S, Maity D. One-step synthesis of hydrophilic functionalized and cytocompatible superparamagnetic iron oxide nanoparticles (SPIONs) based aqueous ferrofluids for biomedical applications. *J Mol Liq.* 2019;274:653–63.

[Article](#) [CAS](#) [Google Scholar](#)

114. Yang M, Cheng K, Qi S, Liu H, Jiang Y, Jiang H, et al. Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. *Biomaterials.* 2013;34(11):2796–806.

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

115. Deri M, Ponnala S, Zeglis B, Pohl G, Dannenberg J, Lewis J, Francesconi L. An alternative chelator for (89)Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). *J Med Chem*. 2014;57.

116. Papadopoulou S, Kolokithas-Ntoukas A, Salvanou EA, Gaitanis A, Xanthopoulos S, Avgoustakis K, et al. Chelator-free/chelator-mediated radiolabeling of colloiddally stabilized iron oxide nanoparticles for biomedical imaging. *Nanomaterials*. 2021. <https://doi.org/10.3390/nano11071677>.

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

117. Chow JCL. Nanomaterial-Based molecular imaging in cancer: advances in simulation and AI integration. *Biomolecules*. 2025;15(3).

118. Aboushoushah SFO. Iron oxide nanoparticles enhancing magnetic resonance imaging: A review of the latest advancements. *J Science: Adv Mater Devices*. 2025;10(2):100875.

[CAS](#) [Google Scholar](#)

119. Chen L, Zang F, Wu H, Li J, Xie J, Ma M, et al. Using pegylated magnetic nanoparticles to describe the EPR effect in tumor for predicting therapeutic efficacy of micelle drugs. *Nanoscale*. 2018;10(4):1788–97.

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

120. Saki H, Nazem F, Fariba F, Sheikhsharbfan R. A high intensity interval training (running and swimming) and resistance training intervention on heart rate variability and the selected biochemical factors in boys with type 1 diabetes. *Diabetes Res Clin Pract*. 2023;204:110915.

Acknowledgements

The authors would like to thank the Clinical Research Development Unit of Farshchian Heart Hospital, Hamadan University of Medical Sciences, Hamadan, Iran, for their assistance throughout the period of study.

Funding

This paper was not funded.

Author information

Authors and Affiliations

Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran

Zahra Shaghaghi

Institute of Nuclear Chemistry and Technology, Dorodna 16 Str, 03-195, Warsaw, Poland

Sahar Nosrati

Clinical Research Development Unit Farshchian Heart Center, Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Ramin Mansouri

Cardiovascular Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

Maryam Alvandi

Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Maryam Alvandi

Contributions

Zahra Shaghaghi contributed to the manuscript/study conceptualization, investigation, writing – review and editing, and supervision; Maryam Alvandi contributed to the writing– review and editing; Sahar Nosrati and Ramin Mansouri participated in writing – original draft manuscript. All authors have contributed significantly to the work reported.

Corresponding author

Correspondence to [Maryam Alvandi](#).

Ethics declarations

Clinical Trial Number

Not applicable

Consent for Publication

The participants signed consent regarding publishing their data

Ethical Approval

This article does not contain any studies with human or animals performed by any of the authors.

Informed Consent

For this type of study, formal consent is not required and informed consent is not applicable.

Conflict of interest

Zahra Shaghaghi, Sahar Nosrati, Ramin Mansouri, Maryam Alvandi declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

[Reprints and permissions](#)

About this article

Cite this article

Shaghghi, Z., Nosrati, S., Mansouri, R. *et al.* Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics. *Nucl Med Mol Imaging* **59**, 315–328 (2025). <https://doi.org/10.1007/s13139-025-00943-z>

Received

10 December 2024

Revised

03 July 2025

Accepted

22 July 2025

Published

26 August 2025

Issue Date

October 2025

DOI

<https://doi.org/10.1007/s13139-025-00943-z>

Keywords

[Radiolabeled magnetic nanoparticles](#)

[SPION](#)

[Theranostics cancer](#)